BCG predicts rising temperatures will increase default risk in 30% of agri and housing loans by 2030, highlighting climate ...

Rising temperatures and climate change may increase default risks in 30% of agricultural and housing loans in the next five ...

ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA ...

Currently, the most widely used vaccine against TB is the Bacillus Calmette-Guérin (BCG). Developed in 1921, the vaccine ...

A new BCG survey highlights significant dissatisfaction among women with consumer goods, financial services, and healthcare ...

The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...

The FDA has authorized an expanded access program that will allow for the use of a recombinant bacillus Calmette-Guerin product.

ImmunityBio (IBRX) is jumping 20% after the drug maker reported that the FDA had approved its use of an "alternative source ...

Climate change poses a significant risk to agricultural and housing loans, with default probability increasing due to rising ...

In a tight economy, disciplined cost management is often a better path than absorbing margin pressures or passing costs to ...